Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Schering Corp. Accepts Federal Contract Ban Under Settlement

This article was originally published in The Pink Sheet Daily

Executive Summary

Schering Sales Corp. is accepting the ultimate penalty under the antikickback statute: a five-year ban from participating in federal government contracts

You may also be interested in...



Schering Settles Off-Label Promotion, Fraud Allegations For $435 Mil.

Settlement with Boston U.S. Attorney’s office includes amendment to Schering-Plough’s existing OIG corporate integrity agreement.

Schering Settles Off-Label Promotion, Fraud Allegations For $435 Mil.

Settlement with Boston U.S. Attorney’s office includes amendment to Schering-Plough’s existing OIG corporate integrity agreement.

Schering-Plough Settles Claritin Kickback Investigation For $345.5 Mil.

Settlement stems from managed care contracts with Cigna and PacifiCare in 1998. “Data processing fees” were in fact disguised rebates that should have been reported to Medicaid, Schering acknowledges.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS060196

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel